| TAEST16001 / Guangzhou Xiangxue Pharma, Athenex |
ChiCTR-OIC-17013872: To Evaluate the Efficacy of NY-ESO-1-specific T Cell Receptor (TCR) Affinity Enhancing Specific T Cell in bone and soft tissue sarcoma |
|
|
| Not yet recruiting | 1 | 20 | | NY-ESO-1（TCR Affinity Enhancing Specific T cell Therapy） | Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center, Xiangxue Life Science Research Center Guangdong Xiangxue Precision Medical Technology Co., Ltd Guangzhou Xiangxue Pharmaceutical Co., Ltd | bone and soft tissue sarcoma | | | | |
CTR20192611: Phase I clinical study of TAEST16001 injection in patients with solid tumors |
|
|
| Completed | 1 | 18 | China | TAEST16001 - Guangzhou Xiangxue Pharma, Athenex | Guangdong Xiangxue Precision Medical Technology Co., Ltd. | Advanced malignant solid tumors, mainly soft tissue sarcomas | | | | |
NCT04318964: TAEST16001 in the Treatment of Soft Tissue Sarcoma |
|
|
| Active, not recruiting | 1 | 12 | RoW | TAEST16001 cells | Sun Yat-sen University, Guangdong Xiangxue Precision Medical Technology Co., Ltd. | Soft Tissue Sarcoma | 04/22 | 05/24 | | |
NCT03462316: NY-ESO-1-specific T Cell Receptor (TCR) T Cell in Sarcoma |
|
|
| Active, not recruiting | 1 | 20 | RoW | NY-ESO-1（TCR Affinity Enhancing Specific T cell Therapy） | Sun Yat-sen University, Guangdong Xiangxue Precision Medical Technology Co., Ltd. | Bone Sarcoma, Soft Tissue Sarcoma | 02/24 | 05/24 | | |
